Wednesday, October 22, 2014
12 noon Eastern, 9 a.m. Paciˇc, 5 p.m. UK, 6 p.m. Central Europe
Jefrey Engelman, M.D., Ph.D.
Harvard Medical School
Michael B. Yafe, M.D., Ph.D.
Massachusetts Institute of
During the webinar, viewers will:
• Gain an understanding of the speciˇc molecules and pathways that are the
targets for rationally designed therapies
• Learn about efforts to overcome resistance to the ˇrst FDA-approved therapy
targeting a hyperactive kinase
• Review mechanisms by which tumor cells resist inhibitors that target cell
survival and growth pathways
• Hear how the rewiring of cell death pathways can sensitize cells to traditional
• Have their questions answered live by the expert panel.
This webinar is the ˇrst in a series focusing on the pathways that allow for cancer
development and progression, the emerging research in identifying and targeting these pathways, and the innovations in the development of cancer treatment
options. Recent advances in our understanding of cancer have revealed that
the disease cannot be understood through simple analysis of genetic mutations
within cancerous cells. Instead, tumors should be considered complex tissues
in which the cancer cells evolve and communicate with the surrounding cellular
microenvironment to promote their own survival and dissemination. Although
therapies against speciˇc signaling proteins or pathways have been remarkably
successful at treating certain cancers, the tumors frequently develop resistance,
leading to even more aggressive forms of the disease.
This webinar will focus on how rewiring of signaling pathways in response to
drug treatment contributes to resistance and how this knowledge can be leveraged to develop more effective treatment strategies.
Michael W. Deininger, M.D., Ph.D.
University of Utah
Salt Lake City, UT
Brought to you by the
Webinar sponsored by
Part 1: Targeting